TriSalus Life Sciences Inc. has reported its financial results for the first quarter of 2025, unveiling a 42% year-over-year increase in net sales, totaling $9.2 million. This also represents an 11% sequential growth over the fourth quarter of 2024. The company has updated its 2025 revenue guidance, confirming an expected growth of at least 50% due to strong commercial momentum and the expanding market adoption of its TriNav platform. Despite the positive revenue outlook, TriSalus does not anticipate achieving adjusted EBITDA-positive or cash flow-positive status in 2025, attributing this to strategic investments in its core liver market and new applications for its PEDD technology. These investments include expanding the company's commercial footprint and developing new clinical applications for its technology. Furthermore, TriSalus has bolstered its financial position with $22 million in gross proceeds from a recent private placement, which will support the expansion of its sales force and clinical registries. The company's strategic priorities aim to balance financial discipline with growth-oriented investments to drive long-term value creation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.